This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Board Selects Michael Astrue As Chairman And Tony Zook As CEO

MOUNTAIN VIEW, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) ("VIVUS"), which recently began selling the obesity drug Qsymia ® (phentermine and topiramate extended-release) capsules CIV in the United States, today announced that its Board of Directors has appointed Michael Astrue to serve as its Chairman and Anthony Zook to serve as its Chief Executive Officer, effective today. Mr. Astrue formerly served as Chief Executive Officer of Transkaryotic Therapies, Chairman of the Massachusetts Biotechnology Council, and Commissioner of Social Security. Mr. Zook formerly served as Executive Vice President , Global Commercial Operations for AstraZeneca and President of Medimmune.

Mr. Astrue said, "We intend to move quickly on our four main goals: 1) expand use of Qsymia through targeted patient and physician education; 2) find the right partner for Qsymia; 3) quickly create a pathway for approval in Europe; and 4) eliminate expenses that are not essential to expanding use of Qsymia. We are thrilled to have an executive of Tony Zook's caliber already pushing hard on these four goals."

Mr. Zook said, "Obesity is a growing disaster for Americans. Aside from its obvious human costs, it creates economic costs due to associated comorbidities such as diabetes, strokes, heart attacks and depression. Our mission is to ensure that at-risk patients and their physicians know about Qsymia and have the information necessary to determine whether Qsymia can help address this devastating condition."

About Qsymia

Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,105.64 -26.22 -0.15%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,825.72 -12.9230 -0.27%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs